Using AI to improve diagnosis and recurrence prediction in thymic tumors
Official title: Artificial Intelligence for Histopathological Classification and Recurrence Prediction of Thymic Epithelial Tumors
Run by Erasmus Medical Center · NCT06301945 · Data updated 2026-11-12
This study is testing if artificial intelligence can help doctors better diagnose thymic tumors and predict the chances of them coming back for patients with these rare cancers.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1020 (estimated) |
| Sponsor | Erasmus Medical Center Academic / other |
| Locations | 1 site (Rotterdam, South Holland) |
| Status | Recruiting |
| Started | August 1, 2023 |
| Main results expected | August 1, 2027 |
| Study ends | August 1, 2027 |
| Registry record updated | March 27, 2024 |
| Trial ID | NCT06301945 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with specific subtypes of thymoma or thymic carcinoma, particularly those with a consensus diagnosis agreement of less than 70%.
✕Probably not a fit
Patients with thymic tumors that do not meet the inclusion criteria or those without a documented recurrence outcome within the specified timeframe may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on thymic epithelial tumors, which are rare cancers located in the anterior mediastinum. It aims to develop artificial intelligence models that utilize digital pathology and clinical data to enhance the accuracy of histopathological classification and predict the risk of recurrence for these tumors. By addressing the inconsistencies in tumor subtyping among pathologists, the study seeks to provide a more reliable prognostic tool for patients diagnosed with various subtypes of thymoma and thymic carcinoma. The research will leverage existing databases from multiple centers to train and validate these AI models.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and better predictions of recurrence for patients with thymic epithelial tumors.
How similar studies have gone: Other studies utilizing AI in pathology have shown promise, indicating that this approach could be beneficial, although the specific application to thymic tumors is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Participants with specific diagnoses are eligible for inclusion in the study. The eligible diagnoses include various subtypes of thymoma and thymic carcinoma, specifically: * Thymoma A * Thymoma AB * Thymoma B1 * Thymoma B2 * Thymoma B3 * Thymic Carcinoma Inclusion is based on a consensus diagnosis with a level of agreement less than 70%. This criterion is applied during the training phase of the model. Recurrence Criteria: Participants with a documented recurrence outcome within a 5-year period are considered eligible for this aspect of the study. This criterion is primarily applied during the validation phase.
Where it's running
-
Erasmus MC
Rotterdam, South Holland, Netherlands Recruiting
Study contacts
- Study coordinator: Anna Salut Esteve Domínguez
- Email: a.estevedominguez@erasmusmc.nl
- Phone: 0107043491
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using hypofractionated radiotherapy for thymic epithelial tumors
This study is testing if a shorter, more intense type of radiation therapy can help people with thymic epithelial tumors after surgery feel better and have fewer side effects compared to the standard treatment.
-
Tislelizumab plus anlotinib as a second-line treatment for thymoma and thymic carcinoma
This trial will test whether combining tislelizumab with anlotinib is safe and can control thymoma or thymic carcinoma in people whose cancer progressed after first-line chemotherapy (with or without immunotherapy).
-
Testing a new treatment for advanced thymic tumors
This study is testing a new drug to see if it can help adults with advanced thymic tumors who haven't had success with other treatments.
-
Analysis and treatment options for thymic cancers
This study is trying to find out how genetic changes in thymic cancers can help doctors create better, personalized treatments for patients.
-
Postoperative Hypofractionated Radiotherapy for Stage II/III Thymic Epithelial Tumors
This study tests whether giving a shorter course of higher-dose radiotherapy after complete tumor removal is safe for adults with Stage II/III thymic epithelial tumors.
-
Target-Selected CAR-NK Cells for B2 Thymoma or Thymic Carcinoma
This study tests whether CAR-NK cells targeting CD30, CD5, or mesothelin can be safely given to adults whose B2 thymoma or thymic carcinoma has come back or not responded to treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.